{"groups":[{"description":"Participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy.","id":"FG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy"},{"description":"Participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion in combination with platinum doublet chemotherapy.","id":"FG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"57"},{"groupId":"FG001","numSubjects":"37"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"188"},{"groupId":"FG001","numSubjects":"88"}],"type":"Participants Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"251"},{"groupId":"FG001","numSubjects":"126"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"251"},{"groupId":"FG001","numSubjects":"126"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All randomized participants."}